Navigenics, Inc. specializes in personalized consumer health and wellness services, with the overall goal of improving health outcomes in individuals. Navigenics aims to educate consumers with knowledge of their genetic predispositions, and then with support from their physician, focus on the prevention of disease, achieve earlier diagnosis, appropriately manage disease or otherwise lessen its impact.
Navigenics has filed 2 patents.
Genetics, Molecular biology, DNA, Population genetics, Biotechnology
Genetics, Molecular biology, DNA, Population genetics, Biotechnology
Latest Navigenics News
Aug 1, 2022
August 01, 2022 12:00 PM Eastern Daylight Time SEATTLE--( BUSINESS WIRE )--Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firm’s Growth Buyout team as a Senior Advisor. In this role, Ms. DuRoss will help the firm build and execute investment strategies to serve the growing pharmaceutical and life sciences markets. This work will be complementary to Ms. DuRoss’ new role as President, Cell and Gene Therapies (CGT) for CSafe Global (“CSafe”), a Frazier portfolio company. Ben Magnano, Frazier Managing Partner, said: “We are thrilled that Amy has chosen to join Frazier as the firm continues to make investments in the pharma services sector, particularly in support of the development and commercialization of advanced therapies. Her experience as an entrepreneur and innovator in the sector will make her an outstanding addition to our team. Amy is a great fit with our firm’s culture, and we are fortunate to have her as a Senior Advisor.” Ms. DuRoss said: “I am excited to be joining Frazier. As advanced therapeutics proliferate in the market, there will be opportunities to make investments in the services and technologies that will be required to enable its growth. I look forward to partnering with Frazier to identify and shape those opportunities.” Ms. DuRoss brings over 25 years of entrepreneurial, corporate development, and patient advocacy experience in precision and personalized medicine. Prior to joining Frazier and CSafe Global, she was the Co-Founder and CEO of Vineti, an enterprise software platform digitizing the unique chain of identity and chain of custody requirements for CGT products, with diverse customer partners ranging from early and mid-stage biotech to Fortune 10 Pharmaceutical companies. Vineti was incubated at GE Ventures, where Ms. DuRoss served as a Managing Director focused on equity investing and new business creation prior to co-founding Vineti. In addition to investment activities, she partnered with GE’s healthcare and life sciences businesses, and external investors and partners, to create and build new companies focused on solving key gaps to industrialization in healthcare and life sciences markets. Before GE Ventures, Ms. DuRoss served as the Chief Business Officer at Navigenics, a personalized genomics company that she also helped sell to Life Technologies (now ThermoFisher). Prior to Navigenics, she was the Co-Founder, Co-Author, and Executive Director of California’s $3 billion stem cell research ballot initiative, which led to the launch of the California Institute for Regenerative Medicine (CIRM). About Frazier Healthcare Partners: Founded in 1991, Frazier Healthcare Partners is a leading private equity firm focused exclusively on the healthcare sector. With over $7.0 billion in total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare services companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier Healthcare Partners, visit www.frazierhealthcare.com . Contacts
Navigenics Frequently Asked Questions (FAQ)
When was Navigenics founded?
Navigenics was founded in 2006.
Where is Navigenics's headquarters?
Navigenics's headquarters is located at 1001 East Hillsdale Boulevard, Foster City.
What is Navigenics's latest funding round?
Navigenics's latest funding round is Acquired.
How much did Navigenics raise?
Navigenics raised a total of $18M.
Who are the investors of Navigenics?
Investors of Navigenics include Life Technologies Corporation, Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, Procter & Gamble, Sequoia Capital and 3 more.
Who are Navigenics's competitors?
Competitors of Navigenics include Life Line Screening, Counsyl, OmeCare, Aviir, VitaPath Genetics and 7 more.
Compare Navigenics to Competitors
Viridis' equipment is a disease marker testing platform to be used at point-of-care.
Life Line Screening is a company focused on preventative health, operating within the healthcare sector. The company offers a range of health screening services, including cardiovascular and stroke screenings, liver, kidney, and diabetes screenings, as well as cancer and bone & joint screenings. These services are primarily aimed at individuals seeking to proactively manage their health and detect potential health risks early. It was founded in 1993 and is based in Cleveland, Ohio.
Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.
XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.
Alerion Biomedical Inc. in San Diego is developing products for the detection, characterization and treatment of disease. The company is developing technologies aimed at studying and managing major diseases including cancer, vascular disorders and hepatobiliary disease. Alerion's latest product line, Fenestra, is revolutionizing the way in vivo imaging is used in basic research and drug development. Founded initially in 1997 as MetaProbe LLC by Research Corporation Technologies and the California Institute of Technology, Alerion Biomedical has grown to encompass a broad range of drug-delivery and medical imaging technologies. Advanced Research Technologies Inc., a Canadian medical device company, acquired substantially all of the imaging technology and product assets of Alerion in March 2006. ART is actively promoting the Fenestra product line.
3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.